Nisa Investment Advisors LLC Sells 221,848 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Nisa Investment Advisors LLC reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 96.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,069 shares of the company's stock after selling 221,848 shares during the quarter. Nisa Investment Advisors LLC's holdings in Amneal Pharmaceuticals were worth $59,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $26,000. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals during the second quarter worth approximately $42,000. nVerses Capital LLC bought a new position in shares of Amneal Pharmaceuticals during the second quarter worth approximately $62,000. Atlanta Consulting Group Advisors LLC acquired a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $61,000. Finally, Xponance Inc. bought a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMRX. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. Finally, Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.40.

Amneal Pharmaceuticals Stock Up 1.4 %

Shares of AMRX stock traded up $0.12 during trading hours on Friday, reaching $8.73. The company's stock had a trading volume of 1,720,455 shares, compared to its average volume of 831,405. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $8.95. The firm's 50 day simple moving average is $8.53 and its 200-day simple moving average is $7.54. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of -12.84 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The business had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.